ASPG and acute lymphoblastic leukemia: However, a recent study by McCormick et al. illustrated that the use of premedication prior to PEG-asparaginase combined with asparaginase level monitoring is the most cost-effective approach in both standard and high risk pediatric ALL patients with 8% and 7% fewer changes to Erwinia-derived asparaginase compared to using monitoring without premedication [29].